LUMO Lumos Pharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LUMO

Price (delayed)

$3.02

Market cap

$24.48M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.18

Enterprise value

-$10.01M

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management ...

Highlights
LUMO's gross profit is up by 35% YoY and by 18% from the previous quarter
The revenue has grown by 35% YoY and by 18% from the previous quarter
The debt has surged by 151% year-on-year and by 117% since the previous quarter
The equity has plunged by 54% YoY and by 23% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://lumos-pharma.com
Peers: NWBO

Key stats

What are the main financial stats of LUMO
Market
Shares outstanding
8.11M
Market cap
$24.48M
Enterprise value
-$10.01M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.88
Price to sales (P/S)
11.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-4.88
Earnings
Revenue
$2.05M
EBIT
-$34.06M
EBITDA
-$34.02M
Free cash flow
-$31.1M
Per share
EPS
-$4.18
Free cash flow per share
-$3.82
Book value per share
$3.45
Revenue per share
$0.25
TBVPS
$4.99
Balance sheet
Total assets
$40.64M
Total liabilities
$13.33M
Debt
$585,000
Equity
$27.31M
Working capital
$33.01M
Liquidity
Debt to equity
0.02
Current ratio
5.69
Quick ratio
5.16
Net debt/EBITDA
1.01
Margins
EBITDA margin
-1,658.7%
Gross margin
100%
Net margin
-1,659.4%
Operating margin
-1,785.2%
Efficiency
Return on assets
-65.3%
Return on equity
-85.6%
Return on invested capital
-414.6%
Return on capital employed
-101.4%
Return on sales
-1,660.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LUMO stock price

How has the Lumos Pharma stock price performed over time
Intraday
-0.66%
1 week
6.71%
1 month
6.34%
1 year
-8.48%
YTD
-5.03%
QTD
7.09%

Financial performance

How have Lumos Pharma's revenue and profit performed over time
Revenue
$2.05M
Gross profit
$2.05M
Operating income
-$36.61M
Net income
-$34.03M
Gross margin
100%
Net margin
-1,659.4%
LUMO's gross profit is up by 35% YoY and by 18% from the previous quarter
The revenue has grown by 35% YoY and by 18% from the previous quarter
The net margin has grown by 19% year-on-year and by 12% since the previous quarter
LUMO's operating margin is up by 15% YoY and by 13% QoQ

Growth

What is Lumos Pharma's growth rate over time

Valuation

What is Lumos Pharma stock price valuation
P/E
N/A
P/B
0.88
P/S
11.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-4.88
LUMO's EPS is down by 13% year-on-year and by 4.5% since the previous quarter
The equity has plunged by 54% YoY and by 23% from the previous quarter
The P/B is 26% more than the last 4 quarters average of 0.7 but 2.2% less than the 5-year quarterly average of 0.9
The P/S is 98% lower than the 5-year quarterly average of 531.3 and 9% lower than the last 4 quarters average of 13.2
The revenue has grown by 35% YoY and by 18% from the previous quarter

Efficiency

How efficient is Lumos Pharma business performance
LUMO's ROE has shrunk by 95% YoY and by 25% QoQ
LUMO's ROA has dropped by 74% year-on-year and by 19% since the previous quarter
LUMO's ROIC has soared by 55% YoY but it is down by 37% QoQ
LUMO's return on sales is up by 19% year-on-year and by 12% since the previous quarter

Dividends

What is LUMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LUMO.

Financial health

How did Lumos Pharma financials performed over time
LUMO's quick ratio is down by 49% year-on-year and by 26% since the previous quarter
The current ratio has declined by 47% year-on-year and by 27% since the previous quarter
The debt is 98% smaller than the equity
The debt has surged by 151% year-on-year and by 117% since the previous quarter
Lumos Pharma's debt to equity has soared by 100% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.